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Abstract
Aims The primary aim of this study is to provide data to inform the design of a randomized controlled clinical trial (RCT) of a
palliative care (PC) intervention in heart failure (HF). We will identify an appropriate study population with a high prevalence
of PC needs deﬁned using quantiﬁable measures. We will also identify which components a speciﬁc and targeted PC interven-
tion in HF should include and attempt to deﬁne the most relevant trial outcomes.
Methods An unselected, prospective, near-consecutive, cohort of patients admitted to hospital with acute decompensated
HF will be enrolled over a 2-year period. All potential participants will be screened using B-type natriuretic peptide and echo-
cardiography, and all those enrolled will be extensively characterized in terms of their HF status, comorbidity, and PC needs.
Quantitative assessment of PC needs will include evaluation of general and disease-speciﬁc quality of life, mood, symptom
burden, caregiver burden, and end of life care. Inpatient assessments will be performed and after discharge outpatient assess-
ments will be carried out every 4months for up to 2.5 years. Participants will be followed up for a minimum of 1 year for
hospital admissions, and place and cause of death. Methods for identifying patients with HF with PC needs will be evaluated,
and estimates of healthcare utilisation performed.
Conclusion By assessing the prevalence of these needs, describing how these needs change over time, and evaluating how
best PC needs can be identiﬁed, we will provide the foundation for designing an RCT of a PC intervention in HF.
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Background
Heart failure (HF) is common, affecting 1–2% of the general
population with the prevalence rising to over 10% in those
aged over 80 years.1,2 HF leads to a reduced life expectancy,
with 5 and 10 year survival rates of 50 and 10% ,respectively,
reported in epidemiological studies.3,4 These poor survival
rates have led to comparisons with cancer.5 Therefore, it
would seem intuitive that some patients with HF may beneﬁt
from specialist palliative care (PC), given the poor survival
and high symptom and care-giver burden associated with this
condition. The World Health Organization (WHO) deﬁnes PC
as an approach that improves the quality of life (QOL) of
patients and their families facing the problem associated with
life-threatening illness, through the prevention and relief of
suffering by means of early identiﬁcation and impeccable
assessment and treatment of pain and other problems, phys-
ical, psychosocial, and spiritual.6 Contemporary HF guidelines
have begun to recommend that PC be considered in patients
with advanced HF refractory to optimal, or maximally
tolerated, contemporary, disease-modifying drug and device
therapies, and where the resultant symptom burden is high
and prognosis poor.7–10 These recommendations are, how-
ever, based on relatively limited evidence and no substantial
and systematic study of the actual and speciﬁc PC needs of
patients with HF (and their caregivers) has been undertaken.
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It is possible that despite a reduced life-expectancy, many
patients with HF do not require speciﬁc or specialist PC—for
example those who remain only slightly functionally limited
by symptoms before a sudden death (and sudden death is
relatively more common in patients with mild symptoms).11
However, a proportion of patients with HF almost certainly
do require PC but, as yet, we do not know how large or small
this group is.
Although many small studies and recent systematic re-
views of these have suggested likely unmet PC needs of
patients with HF,12,13 the true prevalence of these needs
is difﬁcult to quantify for a number of reasons. As well
as being small, most of the studies included highly
selected patients or described cohorts with HF and a vari-
ety of other conditions. Secondly, the patients with HF
were often not clearly described, and because natriuretic
peptides and echocardiography were rarely used, the diag-
nosis of HF in some is uncertain. Furthermore, any differ-
ences in PC needs between HF with preserved ejection
fraction (HF-PEF), which accounts for half of all cases in
some cohorts,14,15 and HF with reduced ejection fraction
(HF-REF) have not been described. Most studies to date
have been cross-sectional and have not, therefore, de-
scribed how PC needs change over time. Finally, many of
the existing studies have used qualitative techniques,
meaning their ﬁndings cannot be quantiﬁed or translated
to other populations. A systematic study describing the
prevalence of PC needs (and the speciﬁcs of these), using
quantiﬁable measures, in an unselected, real-life cohort of
patients with HF, is required. As HF is a condition known
to ﬂuctuate, a single assessment, cross-sectional study
design is unlikely to identify those with a sustained need
for a palliative-intervention, and serial measurement is
essential.
Whether PC is a worthwhile intervention in HF is un-
known because no substantial randomized controlled clini-
cal trial (RCT) has been performed. An RCT of PC in
terminal conditions is, however, possible. One RCT of an
early PC intervention in patients with lung cancer has been
performed, with a suggestion that early PC can improve
QOL and reduce healthcare utilisation.16 However, a more
recent RCT of early PC in patients with advanced cancer
did not show a signiﬁcant improvement in the primary out-
come of QOL in the early PC arm.17 While some of these
results are encouraging, the symptoms and needs of pa-
tients with HF who are approaching the end of life may
be quite different from patients with cancer, and the design
of a potential RCT of PC in HF must consider this. Measures
for assessing PC needs in patients with HF require further
evaluation before being applied in a large RCT in HF. An-
other notable trial was conducted in patients deemed ter-
minally ill as a result of a number of different illness and
were housebound (33% of study participants had HF, 47%
had cancer, and 21% had chronic obstructive airways
disease). This trial compared usual care to usual care plus
PC at home, delivered by a multi-disciplinary team.18 Partic-
ipants in the PC arm experienced signiﬁcantly greater pa-
tient satisfaction, reduced use of medical services and
healthcare costs, and were more likely to die at home than
in a hospital. Although this study was well designed and
informative, the cohort was mixed and the characteristics
of the patients with HF were not clearly described. In par-
ticular, there was no differentiation between HF-PEF and
HF-REF and no description of HF treatment. More recently,
a single centre, RCT of PC in HF, randomized 72 outpatients
with HF-REF NYHA class III/IV to receive either early PC and
HF care together or standard care.19 Assessments of QOL
and symptoms were made at 1, 3 and 6months and pa-
tients were followed up for HF hospitalisations for
6months. The PC arm experienced greater improvements
in QOL and had fewer HF hospitalisations. These results
are encouraging, however, the numbers of patients were
small and patients with HF-PEF were not represented. A
large RCT of PC in HF is needed to build upon these prelim-
inary ﬁndings. Before such a trial can be designed, suitable
outcome measures and tools for identifying patients with
PC needs must be assessed in a real-life population of pa-
tients with HF.
Study aims
Ultimately, the goal of this study is to provide the foundation
for an RCT of a PC intervention in HF. This will include charac-
terisation of an appropriate study population, identifying the
components of a speciﬁc and targeted PC intervention, and
deﬁning potential trial outcomes. To achieve this goal, we will
address the following speciﬁc points:
(1) Describe and quantify the supportive and PC needs of a
cohort of patients hospitalized with HF (and the needs
of their caregivers). Speciﬁcally, describe and quantify
general and disease-speciﬁc QOL, symptom burden,
caregiver burden, mood, performance status, and pref-
erences for end of life (EOL) care of these patients.
(2) Evaluate whether estimated poor prognosis or recog-
nized assessment tools used in other populations (e.g.
patients with cancer) can identify patients with hospi-
talized HF who have PC needs.
(3) Describe the healthcare utilisation of patients hospi-
talized with HF, and describe any differences between
those with and without PC needs.
(4) Using the ﬁndings from items 1–3, design an RCT of a PC
intervention for HF. In particular, we will identify an ap-
propriate population with a high PC need (and describe
how to identify this need), deﬁne the components of an
HF-speciﬁc and targeted PC intervention, and suggest
potential outcome measures for such a trial.
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Rationale and study design
Describing the supportive and palliative care needs
of patients with heart failure
Although there have been descriptions of unmet supportive and
PC needs of patients with HF, these needs have not been de-
scribed using reproducible and quantiﬁable measures in a ‘real
world’ HF population. Any such description should take into ac-
count the WHO deﬁnition of PC,6 and therefore not only make
an assessment of EOL care needs, but also the QOL of patients
and their caregivers, mood and symptom burden.
Quality of life
It is unclear which QOL tool is best in patients with HF, al-
though a combination of a HF speciﬁc and a generic question-
naire may be optimal.20 One of the most commonly used HF
speciﬁc questionnaires is the Kansas City Cardiomyopathy
Questionnaire (KCCQ).21 This has been widely used in a num-
ber of HF studies and has been well validated.22–25 A variety
of generic QOL assessment tools are available and one of
the most widely used is the SF-36,26 which has been validated
in a variety of populations including HF.27,28 This has been
shortened to a 12 question format, while retaining validity,29
in the form of the Short Form 12 (SF-12).29,30
Heart failure not only affects patients’ QOL, but also that of
their caregivers.31 Caregiver QOL can be readily assessed
using a generic tool, such as SF-12, but assessing ‘caregiver
burden’ within a family as a result of HF can also be assessed
using the Zarit Burden Interview.32 This is the most widely
used and validated caregiver assessment tool.33 This tool also
includes an assessment of ﬁnancial strain placed on the care-
giver. This is an important question, as patients within the last
6months of life are potentially entitled to ﬁnancial support in
some countries.
Symptoms
Assessing on-going symptoms should also form part of an
assessment of potential PC needs in HF patients nearing
end-of-life. HF trials tend to focus on the symptoms of dys-
pnoea, fatigue, and oedema. However, it has recently been
shown that patients with HF can develop a multitude of other
symptoms including pain, anxiety, low mood, constipation,
anorexia, nausea, insomnia, and persistent cough.34,35 There
are recognized tools to help make an objective measurement
of symptom burden but these have not been extensively eval-
uated in HF (although they have been in other diseases). The
Edmonton Symptom Assessment System (ESAS)36 has been
validated in cancer37,38 and has previously been used in a
study of patients with HF.39 Scrutiny of the content of the
ESAS and this prior study suggest that it is able to quantify
many of the symptoms experienced in HF.
Mood assessment
The WHO deﬁnition of PC states that PC should identify and
treat psychosocial and physical problems. Therefore, any
assessment of PC needs should detail how QOL, symptom
burden, and end-of-life care potentially affect a patient’s
mood. Indeed, in one RCT of PC use in lung cancer, mood
assessment was used as an outcome measure. Depression,
which is common in HF,40 can affect QOL41 and is associated
with higher morbidity and mortality.42–44 A validated screen-
ing questionnaire for depression is the Hospital Anxiety and
Depression Scale (HADS).45 This has been used in a variety
of populations,46 and is validated in HF.47
End of life care
Most patients with HF die from cardiovascular (CV) causes,
the majority of which are from either worsening HF or
sudden cardiac death.48 There is some evidence that patients
with more severe symptoms of HF are more likely to die from
worsening HF, whereas less symptomatic patients are more
likely to suffer sudden cardiac death.11,49 Not every patient
with HF who dies will have unmet palliative needs, e.g. those
who die from sudden unexpected cardiac death with little
functional limitation. However, patients with progressive HF
may beneﬁt from palliative intervention, and how these indi-
viduals are best identiﬁed is currently unknown.
The majority of HF patients currently die in hospital. Place
of death was recorded in the Assessment of Treatment with
Lisinopril and Survival (ATLAS) trial with more than 50% of
patients dying in hospital. Among those who died out of
hospital, the mode of death was most likely to be sudden.50
These ﬁndings were similar to those of the Sudden Cardiac
Death in Heart Failure Trial (SCD-HeFT) where 58% of
patients died in hospital, 29% died at home, and 7% in an
extended care facility.51 Although these clinical trials are
informative, they included selected populations and are not
representative of ‘real world’ patients with HF. A recent anal-
ysis of data from death certiﬁcates from England and Wales
reported that over 60% of patients dying from HF died in
hospital and <20% died at home.52 However, HF is under-
reported on death certiﬁcates,53,54 and this ﬁnding may not
reﬂect the true experience of patients with HF. Preferred
place of death when recovery seemed unlikely was described
in a study of 80 patients hospitalized with HF which reported
that 50% wished to be cared for at home, 40% wished to
remain in hospital, and 10% were unsure.55 Data comparing
preferred place of death to actual place of death are lacking
in an unselected cohort of patients with HF.
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Patient preference for EOL care has been identiﬁed as a
priority for research into PC need in HF.10,56 Previous studies
suggest that patients often change their mind about preferred
place of death, and there is also poor agreement with their
caregiver on this issue.57 Patients also change their mind about
resuscitation status.58,59 A recent study showed that HF
patients were willing to discuss EOL issues and that patients
were willing to trade QOL for length of life,60 which is contrary
to previous studies.61,62 Although these studies are informa-
tive, they are based on selected cohorts of patients.
Any EOL assessment should not only assess preference for
and actual place of death, but also the patient and caregiver
experience of dying, wherever that occurs. The Views of Infor-
mal Carers for the Evaluation of Services (VOICES) postal
questionnaire has been designed to evaluate relative’s expe-
rience of EOL care of the patients in the last few months of
life.63 This questionnaire has been validated, and a recent
review by the United Kingdom’s Department of Health has
identiﬁed this as an appropriate measurement tool and the
tool of choice in a survey of EOL care.64
Identiﬁcation of patients with palliative care needs
Before an RCT of PC use in HF can be planned, there is a need to
further explore how patients with PC needs can be identiﬁed
and which require the additional services of a specialist PC
service. HF Guidelines suggest using the following factors to
identify patients with HF and PC needs: frequent admission
to hospital with decompensated HF; weight loss and cachexia;
the need for frequent or on-going intravenous therapy; chronic
poor QOL with New York Heart Association (NYHA) class IV
symptoms; and a clinical judgement that the patient is close
to the EOL.7,10 However, predicting prognosis is notoriously
difﬁcult and is recognized as a barrier to PC referral in HF.65 A
number of prognostic models have been described from
various HF cohorts.66 Unfortunately, most models were
developed in chronic ambulatory populations (as opposed to
acutely hospitalized patients) and many were based on
patients not receiving contemporary pharmacotherapy, or did
not include important prognostic factors such as renal function,
B-type natriuretic peptide (BNP)67 (or NT pro BNP) or tropo-
nin.68,69 Use of prognostic models has been suggested as a
way of identifying HF patients who are approaching EOL.70
However, while these models may predict death, there is no
evidence to suggest that prognostic models correlate well with
PC needs.71 This question requires further exploration.72
One approach to try and speciﬁcally identify and assess the
PC needs of HF patients is to use tools currently in develop-
ment for cancer patients, acknowledging that these require
assessment in patients with HF. The Needs Assessment Tool
(progressive disease – cancer) (NAT-PD-C)73 has been
designed speciﬁcally to assess PC needs in cancer patients. It
was designed based upon a literature review of needs of
patients and their caregivers. This assessment is made on a sin-
gle page and completed by the patient’s healthcare profes-
sional. The NAT-PD-C has been validated in cancer
patients74,75 and has been adapted for use in HF with the crea-
tion of the Needs Assessment Tool Progressive Disease Heart
Failure (NAT-PD-HF), with reliability testing and construct vali-
dation.76 However, this tool has yet to be evaluated in a sub-
stantial cohort of patients with HF, and its value in identifying
PC needs in patients with HF is as yet unconﬁrmed. Therefore,
we will carry out these evaluations of the NAT-PD-HF.
Performance status has been used by PC clinicians in both
clinical practice and research as an indication for the likely need
for PC services.77–79 The Karnofksy Performance Scale (KPS)80 is
regarded by many as the gold standard tool for use in cancer
patients.77,78 This instrument has been simpliﬁed and validated
in the form of the Australia-Modiﬁed Karnofksy Performance
Scale (AKPS).81 The AKPS has been developed for use in cancer,
and review of it suggests that it should also provide a suitable
assessment of performance status in patients with HF.
An overview of the study design and the outcome mea-
sures used are illustrated in Figure 1, Panel A.
Study protocol
This will be a 2-year prospective observational study of near-
consecutive patients admitted to hospital with HF. An outline
is described in Figure 2. Patients will be extensively characterized
during their inpatient stay by collecting echocardiographic
(Table 1), demographic, and physiological data, as well as a de-
tailed past medical history. Patient symptom burden, mood,
and QOLwill be assessed during the index admission and repeat-
edly during follow up. The burden on caregivers will also be
assessed. Patient preference for place of death (and actual place
of death, if death occurs), as well as resuscitation preference, will
be recorded. Health care utilisation will be evaluated.
Patient recruitment
Near consecutive patients admitted to the Western Inﬁr-
mary in Glasgow with suspected HF will be screened for
inclusion in the study. HF will be deﬁned according to the
European Society of Cardiology (ESC) guidelines.10 The
Western Inﬁrmary acts as a community hospital for the
North and West of the city, serving a population of about
250 000. All patients admitted with a primary diagnosis of
clinically suspected HF will be approached and asked for per-
mission to access their medical records and to link their re-
cord through National Health Service Scotland Information
Services Division (ISD), allowing identiﬁcation and cause of
hospital readmission and death (including place of death).
Plasma BNP will be measured to aid the diagnosis of HF (and
will provide prognostic information). A ﬁnger prick (12 μL)
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sample of blood will be analysed for BNP using a validated,
point of care, capillary blood sample analysis (Alere HeartCheck
System). Those with a BNP <100pg/mL will be excluded.10 In
addition to elevated BNP, patients must meet the ESC echocar-
diographic criteria for the diagnosis of HF.10,82 Patients with a
conﬁrmed diagnosis of HF will be invited to participate in
the study, and a further sample of blood and urine will be
taken and stored for later batched analysis of biomarkers,
which have prognostic importance in HF. In a previous study
collecting data on near-consecutive HF admissions, we re-
cruited almost 350 patients at the Western Inﬁrmary over a
2-year period.83 and we anticipate similar recruitment in this
study. Based on our earlier study, we anticipate that approxi-
mately 30% of patients will die in the ﬁrst year of follow-up
and approximately 15% per year thereafter.
Inclusion and exclusion criteria are detailed in Table 2.
Patient assessment
Detailed clinical data and data used in validated models of
mortality prediction in HF will be gathered during the index
hospitalisation.66 A full echocardiographic examination will
be carried out according to the European Association of Echo-
cardiography guidelines,84 and assessment of known prog-
nostic variables will be recorded (Table 1). Left ventricular
ejection fraction will be measured using Simpson’s biplane
method.85 Before discharge from hospital, patients will com-
plete the KCCQ and SF-12 questionnaires to assess QOL and
the ESAS questionnaire to assess their current symptom
burden. Mood assessment will be made with the HADS
questionnaire. Patients’ caregivers will be invited to complete
the Zarit Burden Interview to assess caregiver burden.
Performance status will be evaluated using the AKPS. The
NAT-PD-HF will be used to assess the palliative needs of the
patient. One of the investigators will also ask about preferred
place of death and resuscitation preference, in a sensitive
way, in patients thought to be near to death and in those
who exhibit signiﬁcant deterioration during follow-up.
Patients will be asked to consider their preference for place
of care, speciﬁcally, patients will be asked ‘If your health
was to deteriorate in the future, such that you required other
people to care for you, where would you prefer that care to
take place?’ Patients will then be given the following options
to choose from, after explaining this is a hypothetical discus-
sion: in their own home; a nursing or care home; hospital;
hospice; or undecided. Patients will then be asked to consider
Figure 1 Study design.
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their preferred place of care for EOL treatment, speciﬁcally,
patients will be asked ‘If you were to think about the last
few days of hours of life, would you have a strong opinion
or preference for where that care took place?’ Patients will
then be given the following options to choose from, after
explaining this is a hypothetical discussion: in their own
home; a nursing or care home; hospital; hospice; or unde-
cided. Finally, patients will be asked, after an explanation of
what resuscitation is, to consider their preference for resusci-
tation. Speciﬁcally, patients will be asked ‘Do you have a
strong opinion or preference to be resuscitated or not to be
resuscitated in the event of a cardiac arrest’. Patient will be
asked to pick an option from ‘for active resuscitation, not
for resuscitation, or undecided’. The researcher will only ask
these questions where it is felt to be appropriate, in patients
approaching the EOL, and only after making explicitly clear
that the questions relate to research and are not for clinical
purposes. While we recognize the limitations in predicting
likely death in HF, our Ethics Committee does not think it
appropriate that we approach all patients about this question.
Study assessments
Following discharge, patients will be reviewed at an outpa-
tient clinic by a cardiologist, a Heart Failure Liaison Nurse
(HFLN), or both, where evidence-based therapy will be opti-
mized in accordance with ESC guidelines.10 Patients will be
invited to attend for study assessments at 4-monthly intervals
following discharge for a maximum follow-up period of
2.5 years. At these visits, KCCQ, SF-12, HADS, and ESAS
questionnaires will be completed, to detail any potential
change in QOL, mood, and symptom burden over time.
EOL preferences will also be re-evaluated (as appropriate),
including preferred place of care/death and resuscitation
Figure 2 Study protocol.
30 R.T. Campbell et al.
ESC Heart Failure 2015; 2: 25–36
DOI: 10.1002/ehf2.12027
preference. At these study assessments, prognostic markers
will be updated and the NAT-PD-HF will be reassessed. To
ensure a complete follow-up as possible, we will contact
those unable to attend study visits by telephone and offer
home visits where possible.
Follow-up
All patients who consent will be ‘ﬂagged’ using ISD linkage,
ensuring complete follow-up (all will be followed up for a
minimum of 12months). PC could potentially alter Healthcare
utilisation.16 Therefore, the number of hospital admissions,
length of stay, cause of admission, general practitioner (GP)
visits, district nurse (DN) visits, hospice admissions, HFLN
visits, and prescription costs will be recorded. These data in-
cluding date, cause and location of death will be available
from ISD and GP records.
Relatives of deceased patients will be asked to complete
the VOICES EOL postal questionnaire. Relatives will be written
Table 1. Echocardiographic protocol and data
Protocol
MeasurementWindow Doppler 2D/M-mode
Parasternal
Long axis MV & AV colour ﬂow IVSd, LVEDD, LVPWd LV end diastolic dimension (cm/m2)
IVSs, LVESD, LVPWs, LVOT, LA LV end systolic dimension (cm/m2)
RV inﬂow TV CW+colour ﬂow
Short axis
Base AV, TV & PV colour ﬂow
MV MV colour ﬂow
Papillary muscle 2D endocardial & epicardial area LV mass index (g/m2)
apex
Apical
4 chamber MV annulus TDI+ LV inﬂow PW LV volume diastole+ systole, LAA LV EF (%)
MV colour ﬂow, TV colour ﬂow LV diastolic volume (ml/m2)
LV systolic volume (ml/m2)
LV stroke volume (ml)
Cardiac output (L/min)
LV diastolic parameters (E, E/e’, IVRT, E/A)
Left atrial volume (ml/m2)
Valve assessment of structure and function
2 chamber MV colour ﬂow LV volume diastole+systole, LAA LV EF (%)
Left atrial volume (ml/m2)
LV diastolic volume (ml/m2)
LV systolic volume (ml/m2)
5 chamber AV CW+PW+IVRT, AV colour ﬂow
Long axis MV colour ﬂow
RV TAPSE, RAA TAPSE
Right atrial area (mm2)
Subcostal
4 chamber
IVC & hepatic veins IVC diameter RVSP
AV, aortic valve; CW, continuous wave; E, early diastolic ﬁlling; e’, early lengthening velocity; IVC, inferior vena cava; IVRT, isovolumic
relaxation time; IVSd, intraventricular septal diastole; IVSs, intraventricular septum systole; LVEDd, left ventricular end-diastolic dimen-
sion; LVESD, left ventricular end-systolic dimension; LVPWd, left ventricular posterior wall diastole; LVEDs, left ventricle posterior wall sys-
tole; EF, ejection fraction; LAA, left atrial area; LV, left ventricle; MV, mitral valve; PV, pulmonary valve; PW, pulsed wave; RV, right
ventricle; RVSP, right ventricular systolic pressure; TAPSE, tricuspid annular plane systolic excursion.
Table 2. Inclusion/ exclusion criteria
Inclusion criteria Exclusion criteria
• Admitted to hospital with a
primary diagnosis of acute
decompensated HF
• Refusal to participate
• Age ≥18 years • Unable to provide informed
consent/complete study
assessments
• Fulﬁlling the ESC diagnostic
criteria for the diagnosis of HF
○ Confusion/dementia
• HF-REF, HF-PEF and valvular
HF will be included
○ Learning difﬁculties
○ Unable to read or write
English language
○ Moribund
• Readmission
• Geographical reasons, not
from catchment area
• Isolated cor pulmonale
• Acute coronary syndrome
complicated by pulmonary
oedema
ESC, European Society of Cardiology; HF, heart failure; HF-REF,
heart failure with reduced ejection fraction; HF-PEF, heart failure
with preserved ejection fraction.
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to and given the opportunity to opt out prior to the question-
naire being posted.
Data handling and statistical analysis
All data will be managed and analysed by the Robertson Centre
for Biostatistics (University of Glasgow) and the Data and Bio-
statistics Centre of the UK Clinical Research Collaboration Glas-
gow Clinical Trials Unit (CTU). Baseline and follow-up data
(including patient and carer QOL) will be entered into a case re-
port form and then into the study database by experienced
data entry staff. All data will be stored, managed, and analysed
according to CTU standard operating procedures that comply
with appropriate legal and regulatory requirements. We will de-
ﬁne patients in need of PC as those reporting a substantial re-
duction in QOL, marked mood disturbance, or severe
symptoms (as measured by NYHA class, KCCQ, and ESAS), espe-
cially if there is associated caregiver strain (Figure 1, Panel B).
We will test whether the NAT-PD-HF and AKPS tools (and a
prognostic score derived from standard clinical assessments)
identify these patients. Much of the analysis will be descriptive,
using different scores and combinations of scores from the var-
ious patient-reported outcomes to deﬁne a need for PC (Fig-
ure 1, Panel C). We will also assess temporal variations in
QOL, patient symptom burden, and PC needs for the cohort
as a whole and for different patient sub-groups. The relation-
ship between the need for PC as identiﬁed by the NAT-PD-HF
and other clinical and QOL instruments will be analysed using
logistic regression models. The relationship between baseline
characteristics, QOL data, and mortality will be assessed using
logistic regression and time to event analyses. The additional
value of repeated QOL assessments will be evaluated using
time varying covariate Cox models.
Ethical considerations
This study will be conducted according to the principles
outlined in the Declaration of Helsinki.86 The study protocol
has been approved by the West of Scotland Research Ethics
Committee. All participants will be given over 24 h to read
the patient information letter and consider if they wish to
participate before provide written consent. Patient burden
and load have been considered, and patient reported out-
come measures have been chosen to limit the burden placed
on participants. Burden of follow-up study visits has been
reduced by offering participants home visits or providing
door-to-door transport. Our local Ethics Committee has asked
that we only ask preferred place of death in patients thought
to be near to death and in those who exhibit signiﬁcant dete-
rioration during follow-up. While we recognize the limitations
in predicting likely death in HF, our Ethics Committee does
not think it appropriate that we approach all patients about
this question.
Discussion
Performing research in people with serious illness is difﬁcult,
with poor recruitment, and high rates of participant dropout
common,87 perhaps explaining why few studies of PC in HF have
been longitudinal, quantitative, or performed in large cohorts.
Barnes et al. described their experience of recruiting a large co-
hort of elderly patients with HF into a longitudinal study,88 and
reported such problems. They experienced difﬁculties with re-
cruitment and retention of elderly patients, with only 30% of pa-
tients approached agreeing to participate. One of the main
challenges they had was the reliance on a gate-keeper to recruit
participants, in their case the GP (but in other similar studies of-
ten hospital specialists).89 They found some GPs to be over-
restrictive in recruitment, excluding potential participants
for reasons outside the protocol-speciﬁed exclusion criteria,
particularly elderly patients living in care facilities. Other
GPs did not utilize the exclusion criteria, and therefore ineli-
gible patients were also approached. These factors can intro-
duce selection bias, reducing the generalisability of results.
One of the key strengths of our study is the reduction in se-
lection bias by approaching a consecutive, and thus
recruiting a relatively unselected, cohort of hospitalized
patients. We will reduce the aforementioned issues by not
relying on a gate-keeper physician to recruit participants, as
a member of the study team will screen all admissions for po-
tential participants.
Another potential issue highlighted by Barnes et al. was the
identiﬁcation of patients with HF. They searched patient data-
bases for the diagnostic code ‘heart failure’ and combining this
with a search for patients on a regular loop diuretic. Although this
screening method is efﬁcient and has the advantage of high sen-
sitivity, speciﬁcity is likely low. The diagnosis of HF is difﬁcult, espe-
cially HF-PEF,90 and usually requires the combination of clinical
signs and symptoms, natriuretic peptides, and echocardiogra-
phy.10 This highlights a further strength of our study as all poten-
tial participants will be screened using natriuretic peptides and
echocardiography, making the cohort one of the best described
contemporary HF populations in the ﬁeld of palliative care.
Participation burden has also been identiﬁed as a potential
issue affecting retention of participants in any longitudinal
study of patients with HF,88 with some outcome measures,
such as ﬁlling in questionnaires or attending study assess-
ments, becoming more challenging for participants to com-
plete as their condition progresses and their general health
deteriorates. This has been considered, and measures and
study design chosen to reduce participant burden as much
as possible. This is one of the main aims of this study, to pilot
the use of many of the outcome measures over time in a frail
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population, to help inform the design of a large RCT of early PC
intervention in patients with HF.
The main weakness of our study is the exclusion criteria. We
will exclude patients with cognitive impairment such that they
are unable to provide informed consent or complete study as-
sessments, or those unable to complete study assessments be-
cause of language or communication difﬁculties. Although
these criteria are necessary, wewill potentially exclude not only
a common group of patients,91 but those with some of the
greatest needs.92 Targeting inpatients could also result in some
patients being too unwell to participate; however, we feel the
strength of recruiting an unselected hospital cohort outweighs
this potential weakness.
Conclusion
This study will be one of the largest assessing PC needs in a
largely unselected cohort of patients admitted to hospital
with HF, and will be one of the best-described contemporary
HF cohorts. We will assess the prevalence of PC needs and
describe how these needs change over time, and assess
whether those with PC needs can be identiﬁed. In doing, so
we will provide the foundation for designing a large RCT of
an early PC intervention in HF.
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